You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation

Article metrics

Article menu
Clinical/translational cancer immunotherapy
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation

 

Online download statistics by month:

Online download statistics by month: March 2022 to March 2026

AbstractFullPdf
Mar 2022661673249
Apr 2022316326123
May 202224324784
Jun 2022229242104
Jul 202220421060
Aug 202220721340
Sep 202220821744
Oct 202219620357
Nov 202214114330
Dec 202211211220
Jan 202312312547
Feb 202314014038
Mar 202311211374
Apr 2023919442
May 202311211236
Jun 2023868629
Jul 2023838535
Aug 202310210236
Sep 2023848424
Oct 2023818134
Nov 2023818130
Dec 2023636428
Jan 2024454522
Feb 2024575723
Mar 202410711033
Apr 202414414454
May 2024636330
Jun 2024848737
Jul 2024929368
Aug 2024575726
Sep 2024686820
Oct 2024929252
Nov 202412012261
Dec 2024848634
Jan 2025989935
Feb 2025808033
Mar 2025999928
Apr 202511411442
May 2025717242
Jun 2025444415
Jul 2025110
Mar 2026110
Total519652871919